Search

A specialized investment firm is currently investing from its third oncology fund of USD 64 million. The firm generally makes investments in Series A, B or C equity rounds; the firm is not interested in seed rounds. The firm typically makes allocations of $3-8 million, and may either lead investments or act as a co-investor alongside a syndicate. The firm is open to oncology opportunities globally but has recently invested primarily in the USA.

The firm is currently focused on cancer therapeutics. The firm will consider any form of therapeutic molecule in oncology, including small molecules, antibodies or new technologies such as cell therapies. The firm generally invests at the late preclinical stage, from 6-12 months pre-IND, but is also interested in companies with Phase I or Phase II assets.

The firm places high importance on the management team’s scientific rigor and industry experience; the firm prefers to work with entrepreneurs who have led biotech companies previously. NThe firm also considers the strength of the investor syndicate and their alignment of interests.

Subscribe

Featured Posts

An interview with Zishan Haroon, Chairman and General Partner, Julz Co – By Claire Jeong, Research Analyst, LSN Earlier this week, I had the pleasure of speaking with Dr. Zishan “Z” Haroon, Chairman and General Partner of Julz Co. Z has been a tremendous supporter of the Redefining Early Stage Investments (RESI) Conference Series and a […]

By Gregory Mannix, Vice President International Business Development, LSN Life Science Nation’s Redefining Early Stage Investments (RESI) Conference series is a great opportunity to network and make connections with key players that can help move your company to the next phase. The RESI conference series, because of its unique focus and format, is by far […]

An interview with Life Science Nation’s CEO Dennis Ford regarding the up and coming Redefining Early Stage Investments conference series – By Ying Tam, Managing Director, Health Ventures, MaRS With the Redefining Early Stage Investments Conference headed back to MaRS on April 10th, Next Phase would like to revisit this interview between Dennis Ford (CEO, […]

A newly formed Delaware family office investment vehicle representing East Coast-based family interests is looking to invest in ground-breaking life science and medical device technologies. While the firm is very flexible in terms of investment size, they are generally looking to invest a minimum of $0.5 million per round. The firm is open to Investing […]

A venture capital firm partnered with the Chinese Government was founded in 2016, and focuses on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. With the Chinese Government partnership, the firm seeks to bring […]